BioSpace News Archive

The watch will begin shipping in EU as a medical device for continuous measurement of heart rate and arrhythmias at ECG-level accuracy

Biophytis announces the pricing of its previously announced U.S. initial public offering of 12,000,000 new ordinary shares represented by 1,200,000 American Depositary Shares, with each ADS representing 10 ordinary shares, at an initial public offering price of $16.75 per ADS.

PureTech Health plc is pleased to note that its Founded Entity, Vor Biopharma, announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of $18.00 per share.

Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19

XPhyto Therapeutics Corp. is pleased to announce that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months ended December 31, 2020.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021 BIO CEO & Investor Digital Conference

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 a.m. EST.

As gene therapies and editing technologies rapidly advance, it is more urgent than ever to provide updates and information to the rare disease community on how these technologies can be applied across multiple diseases. Global Genes, a leading rare disease patient advocacy organization, is pleased to announce they will be publishing a multimedia series, titled Platforms of Hope: Advances in Gene Therapy and Gene Editing

Truist Virtual Fireside Chat on February 11, 2021 at 1:00 pm ET 10 th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 am ET